Three-year follow-up of posterior capsule opacification after AquaLase and NeoSoniX phacoemulsification

A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials

Purpose

The purpose of this study is to estimate and compare neodymium-doped yttrium aluminum garnet (Nd:YAG) capsulotomy rates for AcrySof ^® and Clareon^® intraocular lens (IOL) materials using historical data from the medical literature and Alcon-sponsored clinical studies.

Methods

Clinical trials that involved the implantation of AcrySof or Clareon monofocal IOLs in subjects with cataract or presbyopia were extracted from the literature and a company repository of clinical studies. The study duration, number of eyes, and cumulative percent of Nd:YAGs for posterior capsule opacification were extracted. Bayesian random effects meta-analyses were conducted to estimate and compare outcomes for the 2 different IOL materials.

Results

A Bayesian random effects, meta-analysis was performed that combined a literature review of published AcrySof Nd:YAG posterior capsulotomy rates and Nd:YAG rates observed in Alcon-sponsored clinical studies of AcrySof and Clareon. Sixteen Alcon studies contained Nd:YAG data suitable for meta-analysis. Three of these Alcon studies contained results for the Clareon material (2 one-year studies, and 1 three-year study). The literature review included 50 papers from 1998 to 2015. In combination, 30,891 eyes were available for analysis and 2040 Nd:YAG procedures were reported in studies with a follow-up duration ranging in length from 4 months to 10 years. The overall probability of performing a Nd:YAG capsulotomy within a year of implant for AcrySof was 1.44% (1.11% to 1.83%) and 0.62% (0.21% to 1.38%) for Clareon. There was small improvement in the probability of Nd:YAG within a year of implant for Clareon lenses of about 0.82% with a 95% credible interval of (0.07% to 1.36%) at 1 year. Results were similar for incidence rates per 100 surgeries in a year: 0.62 (0.21 to 1.40) for Clareon, 1.46 (1.12 to 1.87) for AcrySof, and the difference was 0.84 (0.07 to 1.39) favoring Clareon. At 3 years, the overall probability of performing a Nd:YAG capsulotomy for AcrySof was 4.19% (3.24% to 5.30%) compared with only 1.82% (0.63% to 4.02%) for Clareon.

Conclusion

A meta-analysis of Clareon multi-piece and single-piece clinical data predicts that the cumulative Clareon Nd:YAG probability will be ≤ AcrySof by 2.37% (0.18% to 3.91%) at 3 years. The results indicate that Clareon is likely to perform as well as, and possibly better than, AcrySof in terms of Nd:YAG capsulotomy rates.

Liquefaction for cataract extraction

A systematic review of the recent literature regarding the implementation of the liquefaction in cataract surgery and its short-term and long-term outcomes in various parameters that affect the quality of patients' life, including visual rehabilitation and possible complications was performed based on the PubMed, Medline, Nature and the American Academy of Ophthalmology databases in November 2013 and data from 14 comparative studies were included in this narrative review. Liquefaction is an innovative technology for cataract extraction that uses micropulses of balanced salt solution to liquefy the lens nucleus. Most studies reported that liquefaction is a reliable technology for mild to moderate cataracts, while fragmentation difficulties may be encountered with harder nuclei.

Long-term follow-up of posterior capsule opacification after AquaLase and NeoSoniX phacoemulsification

AIM

To compare the degree of posterior capsule opacification (PCO) after AquaLase and NeoSoniX phacoemulsification methods during an 8-year follow-up period using two types of software.

DESIGN

Prospective, randomized clinical trial.

METHODS

AquaLase was used in the right eye and NeoSoniX in the left eye of each patient with bilateral cataract.

RESULTS

Fifty patients were analyzed 1 year, 46 patients 3 years, and 37 patients 8 years after cataract surgery. Mean EPCO 2000 values were for the AquaLase group 0.324 ± 0.305 and for the NeoSoniX group 0.298 ± 0.341 (P = 0.53) 1 year after surgery, for the AquaLase group 0.582 ± 0.506 and for the NeoSoniX group 0.594 ± 0.515 (P = 0.87) 3 years after surgery, and for the AquaLase group 0.648 ± 0.567 and for the NeoSoniX group 0.673 ± 0.542 (P = 0.30) 8 years after surgery. The OSCA results were for the AquaLase group 0.7097 ± 0.3778 and for the NeoSoniX group 0.8584 ± 0.4323 (P = 0.046) 1 year after surgery, for the AquaLase group 0.9667 ± 0.736 and for the NeoSoniX group 0.9540 ± 0.5250 (P = 0.91) 3 years after surgery, and for the AquaLase group 1,035 ± 0,952 and for the NeoSoniX group 1,103 ± 0,741 (P = 0.44) 8 years after surgery.

CONCLUSION

There was minimal PCO difference between these 2 approaches, AquaLase and NeoSoniX. Neither AquaLase nor NeoSoniX technique was able to prevent a natural progression of PCO.

Sealed-capsule irrigation with distilled deionized water to prevent posterior capsule opacification--prospective, randomized clinical trial

PURPOSE

To evaluate the efficacy and safety of sealed-capsule irrigation (SCI) using distilled water (DW) to prevent posterior capsule opacification (PCO).

MATERIALS AND METHODS

Phacoemulsification was performed in 60 patients. Patients were randomly selected into groups. In the control the capsular bag was mechanically cleaned (MC), in the DW group DW for 3' in SCI was additionally applied. SN60WF IOL was implanted in all eyes. Examinations were performed before and 1, 30, 180 days, one and two years after surgery. Uncorrected and corrected distance visual acuity (UDVA, CDVA), intraocular pressure (IOP), surgically induced astigmatism (K2-SIA), spherical equivalent (SEQ), endothelial cell and the complications were examined. Total PCO score in the area of 1 and 3 mm zone and capsulorhexis (CAPS) were determined using EPCO 2000. One patient was withdrawn from the DW group as he did not report for the examinations.

RESULTS

As far as safety parameters are concerned, no differences were observed between groups in two-year follow-up (p > 0.05). However, in the DW group the endothelial cell loss was higher (p < 0.05). Total PCO score differences were observed in both groups between the areas (p < 0.05). In the CAPS area, both Total PCO score and PCO area were decreased in the DW group (p < 0.05). PCO was also lower within 3 mm zone in the DW group (p < 0.05).

CONCLUSIONS

SCI is a safe procedure and the endothelial cells loss can be associated with the Perfect Capsule™ device (Milvella) in the anterior chamber insertion. DW irrigated for 3' reduces PCO in long-term follow-up.